The meningeal lymphatics: regulators of Aβ immunotherapy?
Authors:
- 1 November 2021
- journal article
- editorial
- Published by Elsevier in Trends in Immunology
- Vol. 42 (11) , 940-942
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NS103506, NS108497, T32-GM007507)
This publication has 10 references indexed in Scilit:
- Landmark Alzheimer’s drug approval confounds research communityNature, 2021
- Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapyNature, 2021
- Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approvalAlzheimer's Research & Therapy, 2020
- Meningeal lymphatic vessels regulate brain tumor drainage and immunityCell Research, 2020
- Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s diseaseNature Medicine, 2020
- Questions EMERGE as Biogen claims aducanumab turnaroundNature Reviews Neurology, 2019
- Amyloid‐β immunotherapy for alzheimer disease: Is it now a long shot?Annals of Neurology, 2019
- Functional aspects of meningeal lymphatics in ageing and Alzheimer’s diseaseNature, 2018
- Development and plasticity of meningeal lymphatic vesselsJournal of Experimental Medicine, 2017
- Structural and functional features of central nervous system lymphatic vesselsNature, 2015